ЗНАЧЕНИЕ КАНДИДАТНЫХ МАРКЕРОВ ГЕНОВ ФНО-а, ИЛ-10, ИЛ-6 ПРИ ТЕРАПИИ БОЛЬНЫХ ДИФФУЗНОЙ В-КРУПНОКЛЕТОЧНОЙ ЛИМФОМОЙ

В литературе описаны работы, в которых изучалось предиктивное значение полиморфизма генов при иммунохимиотерапии неходжкинских лимфом. Вместе с тем небольшое число воспроизведений исследований каждого из маркеров и противоречивость данных свидетельствуют о необходимости валидации получаемых результатов на различных этнических выборках и вариантах лимфом. Целью исследования было: оценить предиктивное значение кандидатных маркеров генов гб1800872 гена ИЛ-10, гб673 гена ФНО-а, гб1800795 гена ИЛ-6 на выборке больных диффузной В-крупноклеточной лимфомой (В-ККЛ) г. Новосибирска, получающих терапию Р-СНОР. Получены данные о возможном предиктивном значении гб1800872 гена ИЛ-10, а также гб1800795 гена ИЛ-6, подтвержденные анализом кривых выживаемости пациентов методом Каплана-Майера. Методом регрессии Кокса показано, что генотип гб1800872 может являться независимым предиктором как общей, так и безрецидивной выживаемости больных диффузной В-ККЛ. Гипотеза об ассоциации гб673 гена ФНО-а с эффективностью терапии Р-СНОР при диффузной В-ККЛ подтверждения не получила.

Sabattini E., Bacci F., Sagramoso C., Pileri S.A. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010; 102(3): 83-7.

Sehn L.H., Gascoyne R.D. Diffuse large B-cell lymphoma: optimizing outc(ome in the context of clinical and biologic heterogeneity. Blood. 2015; 125(1): 22-32.

Coiffier B., Thieblemont C., Van Den Neste E., Lepeu G., Plantier I., Castaigne S., et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Grouped’Etudes des Lymphomes de l’Adulte. Blood. 2010; 116(12): 2040-5.

Gisselbrecht C., Glass B., Mounier N., Singh Gill D., Linch D. C., Trneny M., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the ritux-imab era. J. Clin. Oncol. 2010; 28(27): 4184-90. doi: 10.1200/ JCO.2010.28.1618.

Campo E., Swerdlow S.H., Harris N.L., Pileri S., Stein H., Jaffe E. S. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011; 117(19): 5019-32.

Wang W., Hu S., Lu X., Young K.H., Medeiros L.J. Triple-hit B-cell lymphoma with MYC, BCL-2 and BCL-6 translocations / rearrangements: clinicopathologic features of 11 cases. Am. J. Surg. Pathol. 2015; 39(8): 1132-9. doi: 10.1097/ PAS.0000000000000434.

Wright G., Tan B., Rosenwald A., Hurt E.H., Wiestner A., Staudt L.M. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA. 2003; 100(17): 9991-6.

Lohr J.G., Stojanov P., Lawrence M.S., Auclair D., Chapuy B.,Sougnez C., et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. USA. 2012; 109(10): 3879-84.

Li Y, Gordon M.W., Xu-Monette Z.Y, Visco C., Tzankov A., Zou D., et al. Single nucleotide variation in the TP53 39 untranslated region in diffuse large B-cell lymphoma treated with ritux-imab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013; 121(22): 4529-40.

Pasqualucci L., Trifonov V, Fabbri G., Ma J., Rossi D., Chiaren-za A., et al. Analysis of the coding genome of diffuse largeB-cell lymphoma. Nat. Genet. 2011; 43(9): 830-7.

Voropaeva E.N., Voevoda M.I., Pospelova T.I., Maksimov VN. Prognostic impact of the TP53 rs1625895 polymorphism in DLBCL patients. Br. J. Haematol. 2015; 169(1): 32-5.

Rothman N., Skibola C.F., Wang S.S., Morgan G., Lan Q., Smith M.T., et al. Genetic variation in TNF and IL-10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006; 7(1): 27-38.

Wang S.S., Cerhan J.R., Hartge P., Davis S., Cozen W., Severson R.K., et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res. 2006; 66(19): 9771-80.

Juszczynski P., Kalinka E., Bienvenu J., Woszczek G., Borowiec M., Robak T., et al. Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood. 2002; 100(8): 3037-40.

Lech-Maranda E., Baseggio L., Bienvenu J., Charlot C., Berger F., Rigal D., et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood. 2004; 103(9): 3529-34.

Prochazka V, Papajik T., Gazdova J., Divoka M., Rozmanova S., Faber E., et al. FcyRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy. Neoplasma. 2011; 58(3): 263-70.

Prochazka V, Gazdova J., Papajik T Fc gamma receptor 3a genotype in follicular lymphoma: the end of the story? Reply to “Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone”. Haematologica. 2012; 97(6): 937-942. Haematologica. 2012; 97(11): e45.

Persky D.O., Dornan D., Goldman B.H., Braziel R.M., Fisher R.I., LeBlanc M., et al. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica. 2012; 97(6): 937-42.

Liu F., Ding H., Jin X., Ding N., Deng L., He Y, et al. FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma. DNA Cell Biol. 2014; 33(9): 616-23.

el-Far M., Fouda M., Yahya R., el-Baz H. Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin’s lymphoma. J. Physiol. Biochem. 2004; 60(4): 253-8.

Aydin F., Yilmaz M., Ozdemir F., Kavgaci H., Yavuz M.N., Ya-vuz A.A. Correlation of serum IL-2, IL-6 and IL-10 levels with international prognostic index in patients with aggressive non-Hodgkin’s lymphoma. Am. J. Clin. Oncol. 2002; 25(6): 570-2.

Lech-Maranda E., Bienvenu J., Broussais-Guillaumot F., Warzo-cha K., Michallet A.S., Robak T., et al. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index. Arch. Immunol. Ther. Exp. (Warsz). 2010; 58(2): 131-41.

Giachelia M., Voso M.T., Tisi M.C., Martini M., Bozzoli V., Massini G., et al. Interleukin-6 plasma levels are modulated by a polymorphism in the NF-kB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. Leuk. Lymphoma. 2012; 53(3): 411-6.

Bidwell J., Keen L., Gallagher G., Kimberly R., Huizinga T., McDermott M.F., et al. Cytokine gene polymorphism in human disease: on-line databases, supplement 1. Genes Immun. 2001; 2(2): 61-70.

Alas S., Emmanouilides C., Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis. Clin. Cancer Res. 2001; 7(3): 709-23.

Alas S., Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/para-crine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001; 61(13): 5137-44.

Ying B., Shi Y, Pan X., Song X., Huang Z., Niu Q., et al. Association of polymorphisms in the human IL-10 and IL-18 genes with rheumatoid arthritis. Mol. Biol. Rep. 2011; 38(1): 379-85.

Kube D., Hua T.D., von Bonin F.,Schoof N., Zeynalova S., Kloss M., et al. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin’s lymphoma: an exploratory study. Clin. Cancer Res. 2008; 14: 3777-84.

Tarabar O., Cikota-Aleksic B., Tukic L., Milanovic N., Aleksic A., Magic Z. Association of interleukin-10, tumor necrosis factor-a and transforming growth factor-P gene polymorphisms with the outcome of diffuse large B-cell lymphomas. Int. J. Clin. Oncol. 2014; 19(1): 186-92.

Wang S., Fang Z., Huang Y, Lin Z., Su R. Clinical implications of tumor necrosis factor-а in lymphomas. Zhonghua Xue Ye Xue Za Zhi. 2014; 35(12): 1107-10.

Yri O.E., Ekstram P.O., Hilden V, Gaudernack G., Liestol K., Smeland E.B., et al. Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab. Leuk. Lymphoma. 2013; 54(10): 2205-14.

Relander T., Johnson N.A., Farinha P., Connors J.M., Sehn L.H., Gascoyne R.D. Prognostic factors in follicular lymphoma. J. Clin. Oncol. 2010; 28(17): 2902-13.

Giachelia M., Voso M.T., Tisi M.C., Martini M., Bozzoli V, Massini G. et al. Interleukin-6 plasma levels are modulated by a polymorphism in the NF-kB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. Leuk. Lymphoma. 2012; 53(3): 411-6.

Aschebrook-Kilfoy B., Zheng T., Foss F., Ma S., Han X., Lan Q., et al. Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. J. Cancer Surviv. 2012; 6(1): 102-14. doi: 10.1007/s11764-010-0164-4.

Sagne C., Marcel V, Amadou A., Hainaut P., Olivier M., Hall J. A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects. Cell Death Dis. 2013; 4: e492. doi: 10.1038/cd-dis.2013.24